Pfizer Inc
XHAM:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
XHAM:PFE
Watchlist
Price: 21.465 EUR 0.99% Market Closed
Market Cap: 122B EUR

Relative Value

The Relative Value of one PFE stock under the Base Case scenario is 27.381 EUR. Compared to the current market price of 21.465 EUR, Pfizer Inc is Undervalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PFE Relative Value
Base Case
27.381 EUR
Undervaluation 22%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
73
vs Industry
47
Median 3Y
2.4
Median 5Y
2.5
Industry
2.6
Forward
2.3
vs History
44
vs Industry
26
Median 3Y
14
Median 5Y
13.8
Industry
21.4
Forward
8
vs History
47
vs Industry
31
Median 3Y
11.8
Median 5Y
10.8
Industry
16.4
vs History
11
vs Industry
23
Median 3Y
11.7
Median 5Y
9.4
Industry
22.8
vs History
90
vs Industry
47
Median 3Y
1.7
Median 5Y
2
Industry
2.2
vs History
55
vs Industry
36
Median 3Y
2.9
Median 5Y
3
Industry
2.9
Forward
3
vs History
69
vs Industry
46
Median 3Y
4
Median 5Y
4.3
Industry
5.5
vs History
61
vs Industry
36
Median 3Y
7.6
Median 5Y
8
Industry
13
Forward
7.6
vs History
60
vs Industry
33
Median 3Y
10.4
Median 5Y
10.7
Industry
16.5
Forward
8.6
vs History
33
vs Industry
25
Median 3Y
14.2
Median 5Y
13
Industry
15.6
vs History
36
vs Industry
20
Median 3Y
19.1
Median 5Y
16
Industry
18.7
vs History
87
vs Industry
58
Median 3Y
1
Median 5Y
1.2
Industry
1.9

Multiples Across Competitors

PFE Competitors Multiples
Pfizer Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Pfizer Inc
XHAM:PFE
143.2B EUR 2.3 14.6 7.4 10.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.8 37.2 39.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.3 108.4 158.7
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.8 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14 9.9 11.4
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
FR
Sanofi SA
PAR:SAN
100.2B EUR 1.5 7.3 6.6 6.6
P/E Multiple
Earnings Growth PEG
US
Pfizer Inc
XHAM:PFE
Average P/E: 22.3
14.6
27%
0.5
US
Eli Lilly and Co
NYSE:LLY
54.8
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.3
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
FR
Sanofi SA
PAR:SAN
7.3
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Pfizer Inc
XHAM:PFE
Average EV/EBITDA: 400.4
7.4
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
FR
Sanofi SA
PAR:SAN
6.6
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Pfizer Inc
XHAM:PFE
Average EV/EBIT: 1 712.7
10.1
7%
1.4
US
Eli Lilly and Co
NYSE:LLY
39.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
FR
Sanofi SA
PAR:SAN
6.6
15%
0.4